Social Media Ideas for Mrna Therapeutics

Latest updates for Mrna Therapeutics

Fresh curated links around mRNA therapeutics are collected here so marketers can spot useful updates and turn timely ideas into posts faster.

Post angles to try

Share the most useful takeaway for your audience.

Turn one article into a quick practical checklist.

Ask your audience how this shift affects their work.

Turn angles into scheduled posts

Fresh articles and ideas

Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.

fightaging.org /2 days ago

Creation of Chimeric Antigen Receptor Natural Killer Cells in Situ via Messenger RNA Therapy

Messenger RNA (mRNA) can be delivered into tissues and cells by encapsulating it into lipid nanoparticles (LNPs), and then injecting the nanoparticles. A target cell engulfs a LNP,...

Read source

genengnews.com /1 month ago

RNAV8 Bio Joins ARPA-H Team to Pioneer Programmable RNA Medicines

The PROPEL program aims to control gene expression through RNA structure, building logic-gated RNA therapies that switch on only where and when intended, without altering the genom...

Read source

scitechdaily.com /3 weeks ago

A New RNA Strategy Could Target Thousands of Genetic Disorders

This new approach targets disorders including cystic fibrosis, muscular dystrophy, and some cancers. In lab-grown tissue from a cystic fibrosis patient who did not respond to exist...

Read source

biopharmadive.com /6 days ago

Next-gen RNAi drugmaker City prices $200M IPO

The offering will support a trio of medicines in or nearing clinical testing, as well as earlier research into RNAi treatments that get into tissues outside the liver.

Read source

genengnews.com /2 weeks ago

Sensible Biotechnologies Raises $47M to Expand Next-Generation Platform for mRNA Medicines

Sensible Biotechnologies raised $47 million to scale VECTOR, its integrated platform pairing AI-enabled mRNA design with manufacturing of naturally modified mRNA in living cells, a...

Read source

rna-seqblog.com /1 month ago

Avoiding a sticky situation: how cells stop messenger RNAs from clumping together

RNA sequencing reveals how naturally occurring mRNA sequences may reduce harmful RNA aggregation, offering insights into transcriptome stability and the design of mRNA therapeutics...

Read source

genengnews.com /1 month ago

Inhaled Suppressor tRNA Restores Gene Function in Cystic Fibrosis Models

A preclinical study showed how chemically enhanced suppressor tRNAs combined with a lung-targeted delivery system can restore production of a critical protein in models of cystic f...

Read source

labiotech.eu /1 month ago

Rewriting the rules of genetic medicine with tRNA therapeutics

Our guest today is Dr. Nerissa Kreher, Chief Medical Officer of Alltrna. Nerissa brings two decades of rare disease drug development experience. The post Rewriting the rules of gen...

Read source

biopharmadive.com /3 days ago

Merck KGaA bets on RNAi with $1.3B Silence buyout

The acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.

Read source

wired.com /1 month ago

‘Smart’ Nanoparticles Deliver mRNA Directly to Tumors in New Cancer Therapy

The treatment can reprogram immune cells that have been corrupted by the cancer, strengthening the body’s ability to attack.

Read source

genengnews.com /2 weeks ago

The Epitranscriptome Heads Toward Clinical Necessity

Short-read RNA sequencing reporting the modifications that alter protein output is starting to make epitranscriptomics indispensable for patient selection in precision medicines. T...

Read source

biopharmadive.com /4 weeks ago

RNAi drug specialist ADARx raises $446M IPO

ADARx is the only maker of RNA-based drugs to go public since 2024 and the first RNAi biotech to price an IPO in the U.S. in more than a decade.

Read source

medcitynews.com /6 days ago

City Therapeutics’ Upsized IPO Raises $200M to Bring RNAi Drugs Beyond the Liver

City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering...

Read source

medcitynews.com /3 weeks ago

Gene Silencing-Biotech ADARx Makes Some Noise With $535M Stock Market Debut

ADARx Pharmaceuticals upsized its IPO and raised additional cash through a private placement with partner AbbVie. Lead ADARx program onvuzosiran is in Phase 3 testing for the rare...

Read source

genengnews.com /1 month ago

Moonwalk to Use $70 Million to Develop RNAi Therapies for Obesity, Cardiometabolic Disease

New financing will help Moonwalk Biosciences expand its pipeline of siRNA medicines targeting adipose tissue while building out its proprietary drug discovery platform. The post Mo...

Read source

qchron.com /3 weeks ago

Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential...

Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager

Read source

qchron.com /2 weeks ago

Ractigen Therapeutics Presents Positive First-in-Human Data for RAG-18 at WMS 2026, Establishing Clinical Proof-of-Mecha...

First clinical evidence demonstrating that a systemically delivered small activating RNA (saRNA) can safely upregulate an endogenous target protein in human skeletal muscle in a mo...

Read source

bioengineer.org /2 weeks ago

Lipid Nanoparticles Deliver CAR Instructions to T Cells Without Viruses

Researchers have engineered a custom ionizable lipid nanoparticle that delivers CAR-encoding mRNA into human T cells with over 90 percent efficiency, producing potent antitumor act...

Read source

medcitynews.com /3 days ago

Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and...

Read source

genengnews.com /1 month ago

Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development

Through its entry into Lilly Gateway Labs, Rznomics officials say they plan to accelerate candidate discovery and development across its target gene database bank comprising over 2...

Read source

nanowerk.com /3 weeks ago

A new technique could accelerate the development of RNA therapies

Chemical engineers found a way to rapidly produce lipid nanoparticles of varying sizes, which could make it easier to develop new vaccines and therapeutics.

Read source

biopharmadive.com /1 week ago

Experimental Arrowhead RNAi drug hints at Alzheimer’s benefit

In a first, a subcutaneously administered RNA interference medicine crossed into the brain and plummeted levels of a protein implicated in the disease.

Read source

biopharmadive.com /1 month ago

mRNA cancer vaccines’ biggest barriers to market

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

Read source

bioengineer.org /2 weeks ago

mRNA Vaccine Paired With Radiotherapy Shrinks HER2-Positive Lung Tumors in Mice

A HER2-targeted mRNA lipid nanoparticle vaccine combined with fractionated radiotherapy suppressed tumor growth and reprogrammed the immune microenvironment in a mouse model of HER...

Read source

Turn fresh research into a full content calendar

Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.